.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the public market.The Eli Lilly-partnered biotech expect to detail on the Nasdaq under the icon "BIOA," according to documents submitted along with the Securities as well as Substitution Payment. The business has not publicly discussed an anticipated monetary quantity for the offering.The clinical-stage firm touts lead applicant azelaprag, a by mouth provided small particle slated to get into period 2 testing in combination with semaglutide-- marketed by Novo Nordisk under brand name Wegovy for weight-loss-- in the very first one-half of next year. Semaglutide is actually also marketed as Ozempic as well as Rybelsus through Novo for diabetes.
Apelin receptor agonist azelaprag is designed to mix effectively with GLP-1 medications, improving weight-loss while preserving muscular tissue mass. The investigational medicine was actually discovered to become well-tolerated one of 265 individuals around 8 period 1 trials, according to BioAge.Recently, BioAge got the help of Lilly to operate a test blending azelaprag with the Major Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetes as Mounjaro and Zepbound for weight management. The partners are actually currently conducting a phase 2 test of azelaprag and tirzepatide, along with topline results anticipated in the third fourth of 2025.The biotech is actually likewise considering a the hormone insulin sensitivity proof-of-concept test examining azelaprag as a monotherapy in the 1st fifty percent of next year to assist possible evidence growth. Moreover, the company plans to talk to the FDA for approval in the second fifty percent of 2025 to release individual screening for an NLRP3 prevention targeting metabolic illness and neuroinflammation.BioAge's foreseed move to the general public market follows a small uptick in prepared biotech IPOs coming from Bicara Therapies and also Zenas Biopharma. Zooming out, the latest IPO landscape is actually a "mixed photo," along with top notch firms still debuting on the general public markets, simply in minimized varieties, depending on to PitchBook.